2 results
Approved WMOCompleted
To evaluate the effect of MEDI6012 on infarct size compared with placebo.
Approved WMORecruiting
Primary objectivesPart 1 Dose Escalation for LAVA-1207 alone, LAVA-1207 plus LDSC IL-2, and LAVA-1207 plus pembrolizumab• To investigate the safety and tolerability of treatment in patients with therapy refractory mCRPC.• To determine the…